Amgen Sues Pfizer Over US Pegfilgrastim Biosimilar

Meanwhile aBLA For Pegfilgrastim Is Being Reviewed By FDA

 
• By Akriti Seth

Amgen has filed a US patent-infringement lawsuit against Pfizer’s Hospira over its biosimilar pegfilgrastim rival to Neulasta.

Lwsuit
Amgen’s lawsuit alleges infringement of a protein-purifying patent • Source: Shutterstock

More from Biosimilars

More from Products